

OSTEOPOROSIS Therapy Orders

PHONE 515.225.2930 | **FAX** 515.559.2495

Patient Information	Fax completed form, insurance information and clinical documentation to 515.559.2495.						
Patient Name:			DOB:	Phone:			
Patient Status:	New to Therapy	Continuing Therapy	/ Next Treatm	ent Date:			
Medical Information	n						
Diagnosis: Osteo	oporosis Paget's dis	ease of bone Glu	ucocorticoid-induc	ed osteoporosis			
Disor	der of bone (osteopenia)	Other:					
ICD-10 Code:							
Patient Weight: lbs. (required) Allergies:							
Therapy Order							
Zoledronic Acid Zoledronic Acid 5 mg/100 mL IV x1 dose							
Prolia Prolia 60 mg subcutaneous injection every 6 months x1 year							
Evenity Evenity 210 mg subcutaneous injection once monthly x12 doses							
Lab Orders:		Lak	Frequency:				
Required labs to be drawn by: Infusion Center Referring Provider							
Other orders:							
Provider Information	n						
By signing this form and utilizing our services, you are authorizing <i>Hy-Vee Health</i> and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.							
Provider Name:		Signature:		Date:			
Provider NPI:	Phone:	Fa	x:	Contact Person:			
Opt out of Hy-Vee Health selecting site of care (if checked, please list site of care):							
Service Areas							
Des Moines, IA	West Des Moines, I	A Chicago, II	_ Omaha, i	NE Buffalo, NY	Dallas, TX		
Phoenix, AZ	Other						

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR OSTEOPOROSIS THERAPY

INFOSION CARE			
Patient Information			
Patient Name:	D	OB:	
Required Documentation for Referral Pr	rocessing & Insurance Appro	val	
Include <u>signed</u> and <u>completed</u> order (N	1D/prescriber to complete pag	ge 1)	
Include patient demographic informati	ion and insurance informatior	1	
Include patient's current medication lis	t		
Supporting clinical notes to include any to other therapy	y past tried and/or failed thera	pies, intolerance, benefi	ts or contraindications
Has the patient had a documented of IV biphosphonate)? Yes No	contraindication/intolerance o	r failed trial of conventic	onal therapy (i.e., oral and/or
If yes, which drug(s)?			
Please indicate prior drug therapies: Other:	Boniva Forteo Rec	last Prolia Acton	nel Evista Fosamax
Does the patient have a history of a r		Yes No	
If yes, location(s)?			
Patient is currently taking calcium/vi	tamin D supplementation	Yes No	
Does the patient have a FRAX 10-yea fracture at 3% or more? Yes No		or osteoporotic fracture	at 20% or more OR a hip
Pretreatment t-score:	(Osteoporosis: -2.5 or worse, C	osteopenia: -1.0 or worse)	
Include labs and/or test results to suppo	ort diagnosis		
Other medical necessity:			

Required Information

Serum calcium within 6 months (required for all therapies) – attach results

Serum creatinine within 60 days (for Zoledronic Acid) - attach results

Serum alkaline phosphatase (Paget's diagnosis) - attach results

DEXA scan (osteo) - attach

CT scan/X-ray (Paget's diagnosis) – attach

Tried and failed therapies

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.